Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 “Lithium in Brain” Study Conducted at Massachusetts General Hospital
— Topline data expected in first quarter of 2026 — Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structurepharmacokinetics in healthy subjects Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar […]